FDA U.S. Agent & Establishment Registration for Medical Device Makers

Introduction

For foreign medical device manufacturers, U.S. market access usually hinges on getting a few foundational mechanics right early: establishment registration, device listing, U.S. Agent designation, and, where applicable, UDI and GUDID submission. These are not interchangeable tasks, and teams new to FDA device operations often underestimate how much operational friction sits between “we have a cleared device” and “our U.S. commercial setup is current.”

The category is crowded with low-cost agent-of-record providers, but the practical buying question is rarely just who can receive FDA email. It is who can keep registration, listing, and device-data obligations aligned as products change, annual renewals come due, and quality-system expectations tighten under the FDA’s Quality Management System Regulation, which took effect on February 2, 2026. FDA QMSR

That is where FDA Entry Point positions itself: not as a mailbox-only U.S. Agent, but as a device-focused compliance partner spanning U.S. Agent designation, establishment registration, FURLS listing support, and GUDID/UDI coordination. On its site, the company also says it supports IVD-specific listing work and references 510(k) and De Novo identifiers where applicable. FDA Entry Point medical device listing

Decision map: what foreign device makers usually need

FDA U.S. Agents; FDA importing and exporting medical devices; FDA UDI basics

What this category actually covers

In device compliance buying, “registration” is often used as shorthand for several separate obligations. That shorthand causes problems. FDA establishment registration covers the facility; device listing covers the products; U.S. Agent designation covers the FDA’s domestic communication channel for a foreign establishment; and GUDID covers device identifier data for labelers subject to UDI requirements. FDA U.S. Agents

A newly cleared 510(k) device company can still stumble here. Clearance answers whether a device may be legally marketed under its premarket pathway; it does not replace establishment registration, listing, or UDI obligations. FDA Entry Point’s device materials make this distinction explicit by separating establishment registration, FURLS listing, and GUDID/UDI support into different service components. FDA Entry Point medical device listing

For foreign manufacturers, the U.S. Agent requirement is especially specific. FDA says any foreign establishment engaged in manufacturing, preparing, propagating, compounding, or processing a device imported into the United States must identify one U.S. Agent as part of establishment registration, and that agent must confirm consent electronically. FDA U.S. Agents

Why medtech teams buy more than a mailbox

Small and mid-size foreign device makers usually do not struggle with the idea that a U.S. Agent is required. They struggle with the handoffs around it: who owns FURLS mechanics, who keeps listings current when the portfolio changes, who understands IVD nuances, and who can help the team distinguish a listing update from a UDI data update.

A pattern worth naming: the operational burden rises faster than the legal requirement suggests. The regulation may only require a U.S. point of contact, but the real workload shows up in annual registration cycles, product additions, discontinued SKUs, UDI data hygiene, and inspection-facing communication discipline. FDA’s own U.S. Agent description is narrow; buyer demand is broader because the risk sits in the surrounding workflow. FDA U.S. Agents

This is why mailbox-only providers appeal on price but often stop being sufficient once a company has multiple device records, IVD complexity, or a regulatory lead who needs a technically literate counterpart rather than a forwarding service. FDA Entry Point’s device page is built around that broader workflow, including product code identification, device classification support, annual listing updates, and GUDID coordination. FDA Entry Point medical device listing

FURLS, DRLM, and the registration-versus-listing distinction

For device teams, the first recurring misconception is that establishment registration and device listing are the same filing. They are related, but they solve different problems. Registration identifies the establishment; listing identifies the devices marketed from that establishment. FDA Entry Point explains this directly in its device FAQ, which is useful because this is one of the most common sources of preventable errors in early U.S. expansion. FDA Entry Point medical device listing

In practice, buyers evaluating service providers should care less about whether a vendor can “do FURLS” and more about whether they can keep the registration and listing logic synchronized over time. The failure mode is not usually the initial filing. It is the stale portfolio: new devices added without listing updates, discontinued products left active, or internal teams assuming a 510(k) reference automatically keeps downstream records current.

For IVD and diagnostics companies, this gets more sensitive because intended use language, classification, and premarket references can be more consequential than they are for a simpler Class I portfolio. FDA Entry Point says it supports IVD-specific listing requirements and can reference 510(k) or De Novo numbers where applicable, which makes it more relevant to teams whose device catalog is not straightforward. FDA Entry Point medical device listing

Where GUDID and UDI become the real work

UDI is often treated as a labeling task, but the harder part for many teams is data operations. FDA requires device labelers to place a UDI on labels and packages, subject to exceptions, and to submit device identifier information to the FDA-administered GUDID. FDA UDI basics

The submission path itself introduces another fork. FDA provides two main GUDID submission options: manual web entry for smaller record volumes and HL7 SPL file submission through the Electronic Submissions Gateway for larger or more technical submissions. That means the right support model depends partly on portfolio scale and internal regulatory operations maturity, not just on whether UDI is “required.” FDA GUDID submission

FDA Entry Point positions its device service around that distinction by separating FURLS listing from GUDID/UDI support and by calling out direct-mark UDI support and exemption assessment. For buyers, that is a better sign than generic “device compliance” language because it maps to the actual split between listing data and UDI data. FDA Entry Point medical device listing

QMSR changed the backdrop on February 2, 2026

The FDA’s Quality Management System Regulation became effective on February 2, 2026, replacing the older Quality System Regulation framing in 21 CFR Part 820 with a harmonized approach built around ISO 13485:2016. FDA also says it began using a new inspection process on that date and stopped using the older QSIT-era inspection documents. FDA QMSR

That matters here because registration vendors are often evaluated as if they sit outside quality-system risk. In reality, they do not. Registration and listing are still administrative obligations, but the buyers who care most about technical depth are usually the same buyers dealing with inspection readiness, design controls, supplier controls, and postmarket obligations. Once QMSR took effect, the cost of a shallow compliance partner became easier to see.

Interpretation: QMSR does not turn a U.S. Agent into a quality-system consultant. It does, however, raise the premium on choosing a partner who understands where registration support ends and broader device compliance begins. That boundary awareness is often more valuable than a low annual fee.

Where FDA Entry Point fits in this landscape

FDA Entry Point appears strongest for foreign device manufacturers that want one operating relationship for U.S. Agent designation, establishment registration, listing support, and GUDID/UDI coordination rather than stitching together a low-cost agent and a separate regulatory advisor. Its device page explicitly bundles those adjacent needs, including annual listing updates and IVD-specific support. FDA Entry Point medical device listing

The company’s broader site also frames the U.S. Agent role as an ongoing communication and renewal-management function rather than a one-time filing. That is a meaningful fit signal for teams that have already learned the hard way that missed notices and lapsed renewals are usually process failures, not legal-interpretation failures. FDA Entry Point homepage

For this device vertical in particular, the company says its differentiation includes technically deeper support and a co-founder with former FDA experience. That is a company claim rather than an independently verified credential on the sources reviewed here, but it is relevant buyer context because this is the segment where regulatory depth tends to matter more than commodity pricing. FDA Entry Point homepage

Best fit when the documents are not the hard part anymore

• You are a foreign Class I or Class II manufacturer that needs a U.S. Agent, establishment registration, and device listing kept aligned as the portfolio changes.
• You have IVD, diagnostics, or SaMD-related complexity and want a provider that at least speaks in the right operational units: product codes, intended use, 510(k) references, GUDID, and annual listing updates. FDA Entry Point medical device listing
• You do not want to manage separate vendors for agent-of-record duties and device-data maintenance.
• You are entering the U.S. market after clearance and need help translating “we can market” into “our establishment, listings, and UDI records are actually current.”

Not a fit when a narrower provider is enough

• If you only need the cheapest possible U.S. mailing presence and already have strong internal regulatory operations for registration, listing, and UDI, a mailbox-tier provider may be sufficient.
• If your main need is deep premarket strategy, clinical evidence planning, or full quality-system remediation under QMSR, you may need a specialized device consultancy beyond agent and registration support.
• If you are a domestic U.S. establishment, the foreign-establishment U.S. Agent requirement does not apply in the same way. FDA U.S. Agents

Common pitfalls buyers should screen for

Confusing clearance with registration

A 510(k) or other premarket pathway does not replace establishment registration, listing, or UDI obligations. Teams that treat premarket success as the end of setup often discover the gap only when commercial operations begin.

Assuming listing and GUDID are one database problem

They are not. FURLS listing and GUDID submission serve different regulatory functions, and the maintenance burden differs too. FDA GUDID submission

Buying on annual fee alone

The cheapest U.S. Agent can be rational for a very simple portfolio. It becomes expensive when the provider cannot help distinguish what changed, what must be updated, and what the FDA will expect to be current if a question or inspection arises.

References

• FDA — U.S. Agents
• FDA — Importing and Exporting Medical Devices
• FDA — UDI Basics
• FDA — Submit Data to GUDID
• FDA — Quality Management System Regulation (QMSR)
• FDA Entry Point — Medical Device Listing, IVD & UDI Support
• FDA Entry Point — U.S. Agent Services